The Department of Health – Abu Dhabi (DOH) signed a historical Memorandum of Comprehension (MOU) with a set of leaders of the global and local sector to establish a collaborative framework that will shape the future of medical care.
Doh’s partners in the new initiative are Purehealth, Technological University of Khalifa (KU), Illumina, M42, Institute of Major Vida Abu Dhabi (IHLAD) and the University of New York Abu Dhabi (Nyuad).
Abu Dhabi Health Alliance
The agreement, signed duration of ABU Dhabi Global Health Week 2025 (ADGHW), reflects a shared ambition aligned with Doh’s vision to establish one of the world’s smartest health systems, by-popWike, and genre, and genres, and genres, and genre Groups, and genres, and genres, and genres, and. Genor, genor, genor, genorce and genor, genorce. Innovation.
The new systems must be developed particularly in critical areas such as Oncology, strange genetic diseases and metabolic disorders.
أ 8Gue دائرة الصحة – أ ask ش ometer شراكة ipp كة م ج Orth LF ة نيو Bon Bill ك أ scar ، وشركة “إلو Under bas” ، وجامة ويفة، imm ع “imm” imm “imm” و “imm” و “imm ث” imm “و” imm و Asion ” “IMM IMTT ع ISHMENT الحياة الصحية، لط Let’s go to ETT DY DY KSDY PHDY DYDY DYDY PHDY DY CRIPTION ا MORE والأ IC راض الناد OMETER ة. pic.twitter.com/fozwa2tzbl
– دائرة الصحة – أ Asket (@Dohsocial) April 15, 2025
Dr. Asthma Al Mannaei, Executive Director-Salud-Salud Sector of Life Sciences in Doh, said that Abu Dhabi leads the transformation of health systems by taking advantage of science, technology and genomics to build a model of attention ready for the future.
“Precision medicine rephes a fundamental change of a unique approach to deeply personalized, preventive and proactive medical care. Through such strategic associations, we are positioning the Emirate as a global life said,” Al.
The collaboration of multiple interested parties will focus on establishing genomic and health health programs of the population adapted to Emirati and regional populations.
It will also focus on the launch of research and development initiatives in advanced therapies such as cell -based therapy and treatments and support the integration of precision medicine into clinical practice, through pharmacogenomics and genome tests.
In addition, the Association will build artificial intelligence (AI) and digital platforms for the analysis of genomic data and personalized patient care, as well as education and training roads to develop local experience in genomic and precision medicine.
